US equities |
MU $968.12 ▲+4.24% META $610.73 ▼-1.53% TSLA $402.44 ▼-1.23% SPCX $143.76 ▼-3.24% NVDA $216.70 ▼-0.57% SNDK $1,379.00 ▲+5.68% GOOGL $323.68 ▲+0.97% SKHY $164.30 ▲+13.03%
FinancialContent

Alvotech - Ordinary Shares (NQ:ALVO)

4.925 +0.175 (+3.68%)
Delayed Quote Updated: 2:06 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
From Alvotech
Via GlobeNewswire
News headline image
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
News headline image
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
From Alvotech
Via GlobeNewswire
News headline image
Alvotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
From Alvotech
Via GlobeNewswire
News headline image
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Alvotech SA (NASDAQ:ALVO) Surpasses Q2 2025 Estimates with Strong Revenue and EPS Growth ↗
Alvotech SA (NASDAQ:ALVO) reported strong Q2 2025 earnings, beating revenue and EPS estimates with 41% growth. Shares surged 8.5% post-announcement. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Why Is Alvotech Stock Trading Higher On Wednesday? ↗
Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches. 
Via Benzinga
News headline image
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2025 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
From Alvotech
Via GlobeNewswire
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >